Compounds > halicyclamine a
Page last updated: 2024-11-12

halicyclamine a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

halicyclamine A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10479489
CHEMBL ID461499
SCHEMBL ID3130992
MeSH IDM0463033

Synonyms (4)

Synonym
halicyclamine a
CHEMBL461499
SCHEMBL3130992
(4e,6z,14s,19z,21z,29s,30r)-1,16-diazatetracyclo[27.3.1.112,16.014,30]tetratriaconta-4,6,12,19,21-pentaene

Research Excerpts

Effects

ExcerptReferenceRelevance
"Halicyclamine A has been isolated originally as one of the active constituents inhibiting inosine 5'-monophosphate dehydrogenase (IMPDH)."( Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
Arai, M; Baughn, A; Hashizume, H; Ishida, S; Jacobs, WR; Kobayashi, M; Matsumoto, M; Pruksakorn, P; Sobou, M; Vilchéze, C, 2008)		2.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID344029Bactericidal activity against Mycobacterium bovis BCG assessed as decrease in CFU at 10 ug/ml after 4 weeks2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344026Antitubercular activity against Mycobacterium fortuitum ATCC 9820 after 14 days2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344012Antitubercular activity against Mycobacterium smegmatis MC2 155 under hypoxic condition after 96 hrs by MTT method2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344016Antitubercular activity against Mycobacterium tuberculosis H37Ra under hypoxic condition after 14 days by MTT method2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344014Antitubercular activity against Mycobacterium bovis BCG under hypoxic condition after 14 days by MTT method2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344030Bactericidal activity against Mycobacterium tuberculosis H37Rv assessed as decrease in CFU at 20 ug/ml after 11 to 28 days2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344027Antitubercular activity against Mycobacterium aurum ATCC 23366 after 14 days2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID1601820Antimycobacterial activity against Mycobacterium tuberculosis H37Ra2019European journal of medicinal chemistry, Mar-01, Volume: 165Marine natural products as potential anti-tubercular agents.
AID344033Antitubercular activity against guaB2 gene over-expressed Mycobacterium smegmatis MC2 155 ICHO10032008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344024Antitubercular activity against Mycobacterium intracellular ATCC 35761 after 14 days2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344019Antitubercular activity against isoniazid-resistant Mycobacterium tuberculosis H37Rv ATCC 35822 after 14 days2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344021Antitubercular activity against streptomycin-resistant Mycobacterium tuberculosis H37Rv ATCC 35820 after 14 days2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344020Antitubercular activity against rifampicin-resistant Mycobacterium tuberculosis H37Rv ATCC 35838 after 14 days2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344011Antitubercular activity against Mycobacterium smegmatis MC2 155 under aerobic condition after 24 hrs by MTT method2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344023Antitubercular activity against Mycobacterium avium ATCC 35712 after 14 days2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344013Antitubercular activity against Mycobacterium bovis BCG under aerobic condition after 7 days by MTT method2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344032Antitubercular activity against guaB1 gene over-expressed Mycobacterium smegmatis MC2 155 ICHO10022008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344031Antitubercular activity against Mycobacterium smegmatis MC2 155 ICHO1001 with pMV261 transformant2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344025Antitubercular activity against Mycobacterium kansasii ATCC 35775 after 14 days2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344017Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 25618 after 14 days2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID1601822Antimycobacterial activity against Mycobacterium bovis BCG2019European journal of medicinal chemistry, Mar-01, Volume: 165Marine natural products as potential anti-tubercular agents.
AID344028Bactericidal activity against Mycobacterium smegmatis MC2 155 assessed as decrease in CFU at 10 ug/ml after 4 days2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344018Antitubercular activity against ethambutol-resistant Mycobacterium tuberculosis H37Rv ATCC 35837 after 14 days2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344294Antitubercular activity against guaB3 gene over-expressed Mycobacterium smegmatis MC2 155 ICHO10042008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID344015Antitubercular activity against Mycobacterium tuberculosis H37Ra under aerobic condition after 7 days by MTT method2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
AID1601821Antimycobacterial activity against Mycobacterium smegmatis2019European journal of medicinal chemistry, Mar-01, Volume: 165Marine natural products as potential anti-tubercular agents.
AID344022Antitubercular activity against Mycobacterium tuberculosis Kurono ATCC 35812 after 14 days2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.63 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		3.5920carbohydrazideantitubercular agent;
drug allergen
gliotoxin
Gliotoxin: A fungal toxin produced by various species of Trichoderma, Gladiocladium fimbriatum, Aspergillus fumigatus, and Penicillium. It is used as an immunosuppressive agent.. gliotoxin : A pyrazinoindole with a disulfide bridge spanning a dioxo-substituted pyrazine ring; mycotoxin produced by several species of fungi.		3.3110dipeptide;
organic disulfide;
organic heterotetracyclic compound;
pyrazinoindole		antifungal agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
immunosuppressive agent;
mycotoxin;
proteasome inhibitor
puupehenone
[no description available]		3.3110
24-methylenecholesterol
24-methylenecholesterol: RN given refers to (3beta)-isomer; structure. 24-methylenecholesterol : A 3beta-sterol having the structure of cholesterol with a methylene group at C-24.		3.31103beta-hydroxy-Delta(5)-steroid;
3beta-sterol		mouse metabolite
brevianamide f
brevianamide F: isolated from the endophyte from Aspergillus fumigatus associated with Melia azedarach L that could be used to develop a natural eco-friendly herbicide.structure in first source. brevianamide F : A pyrrolopyrazine that is hexahydropyrrolo[1,2-a]pyrazine-1,4-dione bearing an indol-3-ylmethyl substituent at position 3 (the 3S,8aS-diastereomer, obtained by formal cyclocondensation of L-tryptophan and L-proline).		3.3110dipeptide;
indoles;
pyrrolopyrazine		metabolite
dihydropyridines
Dihydropyridines: Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position.		2.0510
epinephrine
ircinal A: from an Indonesian Acanthostrongylophora sponge with activity against infectious, tropical parasitic, and Alzheimer's diseases; structure in first source		3.3110
caulerpin
caulerpin: pigment from green algae, Caulerpa lamourouxii; structure		3.3110
sclerotiorin
sclerotiorin: isolated from monoverticillate Penicillia; RN given for (R-(R*,S*-(E,E)))-isomer; structure in first source		3.3110azaphilone
pseudopteroxazole
pseudopteroxazole: structure in first source		3.3110tetralinsmetabolite
manzamine a
manzamine A: RN given refers to (1R-(1R*,9Z,13S*,13aR*,20aR*,21aR*)-isomer; RN for cpd without isomeric designation not avail 12/92. manzamine A : An alkaloid of the class of beta-carbolines isolated from Haliclona and Acanthostrongylophora. It exhibits inhibitory activity against Glycogen Synthase Kinase-3 (EC 2.7.11.26).		3.3110alkaloid;
beta-carbolines;
isoquinolines		animal metabolite;
anti-HSV-1 agent;
antimalarial;
antineoplastic agent;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
marine metabolite
1,4-dihydroxy-2-methoxy-7-methylanthraquinone
[no description available]		3.3110
proximicin b
proximicin B: antineoplastic agent isolated from Verrucosispora; structure in first source		3.3110
piperidines
Piperidines: A family of hexahydropyridines.		2.9640
sch 419560
Sch 419560: isolated from Pseudomonas fluorescens; structure in first source		3.3110
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		3.3110cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
4-deoxybostrycin
4-deoxybostrycin: crystalline red pigment from culture filtrate of Alternaria eichhorniae with antibacterial & phytotoxic activity; structure given in first source		3.3110
ConditionIndicatedRelationship StrengthStudiesTrials
Koch's Disease
[description not available]		03.1210
Tuberculosis
Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.		03.1210